riskScore Validations Study
Myriad was excited to present the validation study for riskScoreTM at this year’s annual San Antonio Breast Cancer Symposium, which showed riskScore’s great clinical value.
As you know, riskScore is a clinically validated risk model that can help provide a personalized risk of breast cancer for eligible patients*. The model does this by assessing over 80 Single Nucleotide Polymorphisms (SNPs) known to be associated with breast cancer, combined with the Tyrer-Cuzick** model.
Summary of the validation study
1. The remaining lifetime and 5-year breast cancer risk estimates determined by riskScore were highly significant
2. riskScore added significant breast cancer risk discrimination independent of that captured by Tyrer-Cuzick for both remaining lifetime risk and 5-year risk
Resources to help you review and understand this data
1. Webinar with the lead author, Elisha Hughes, PhD, walking through the methodology and results in detail: https://vimeo.com/247363805
2. The poster presentation from the San Antonio Breast Cancer Symposium:https://myriad-web.s3.amazonaws.com/publications/45923666-SABCS%202017%20Hughes_Presented%20on%20December%206,%202017.pdf
3. Your local Myriad Account Executive and Regional Medical Specialist
4. Myriad’s Medical Services Department: 800-469-7423 ext. 3850 or emailinghelpmed@myriad.com

*Eligible patients are women of solely European ancestry who have no history of breast disease or a known familial mutation in a gene associated with breast cancer
**Reference: Tyrer J, et al. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004 23:1111-30.